Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Price:
957 USD
3.57%
Market Closed
Updated:
May 4, 2024
Regeneron Pharmaceuticals Inc
Net Income (Common)
|
Regeneron Pharmaceuticals Inc
Net Income (Common) Peer Comparison
Comparables:
ABBV
GILD
AMGN
MRNA
VRTX
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
25%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$4.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$484m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-20%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$6.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
|
Moderna Inc
NASDAQ:MRNA
|
Net Income (Common)
-$4.7B
|
CAGR 3-Years
-85%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
See Also
What is Regeneron Pharmaceuticals Inc's Net Income (Common)?
Net Income (Common)
4B
USD
4B
USD
Based on the financial report for Dec 31, 2023, Regeneron Pharmaceuticals Inc's Net Income (Common) amounts to 4B USD.
What is Regeneron Pharmaceuticals Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
25%
25%
Over the last year, the Net Income (Common) growth was -9%. The average annual Net Income (Common) growth rates for Regeneron Pharmaceuticals Inc have been 4% over the past three years , 10% over the past five years , and 25% over the past ten years .
You don't have any saved screeners yet
